Get started
Author

Chiara Boccaccio

Observed names: Boccaccio, Chiara, Chiara BOCCACCIO
ORCID: 0000-0003-1019-5983
Observed ORCID: 0000-0003-1019-5983
OpenAlex ID: A5066899111
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors
2023 · Paolo Manca, Francesca Corti, et al. · European Journal of Cancer · 62
PDF
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2023 · Claire Gallois, Matteo Landi, et al. · Clinical Cancer Research · 33
PDF
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
2025 · R. Moretto, D. Rossini, et al. · European Journal of Cancer · 6
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study
2023 · Federica Marmorino, Lorenzo Faggioni, et al. · Future Oncology · 5
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy
2025 · Guglielmo Vetere, Marco Maria Germani, et al. · Therapeutic Advances in Medical Oncology · 4
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma
2023 · Marco Maria Germani, Chiara Boccaccio, et al. · The Oncologist · 4
PDF
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration
2024 · Roberto Moretto, Daniele Rossini, et al. · JCO Precision Oncology · 3
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile.
2024 · Andrea Pretta, Pina Ziranu, et al. · Journal of Clinical Oncology · 3
PDF
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.
2023 · Claire Gallois, Matteo Landi, et al. · Journal of Clinical Oncology · 3
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorithm
2025 · Roberto Moretto, Chiara Boccaccio, et al. · European Journal of Cancer · 2
Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.
2024 · Paolo Ciracì, Veronica Conca, et al. · Journal of Clinical Oncology · 1
PDF
Circulating, extracellular vesicle-associated tissue factor in cancer patients with and without venous thromboembolism
2023 · Valentina Lami, Roberta Pancani, et al. · 1
Data from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2023 · Claire Gallois, Matteo Landi, et al. · 1
Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026 · Vincenzo Nasca, Gabriele Tinè, et al. · Cancer Research Communications
PDF
Supplemental Figure 5 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 6 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 1 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2025 · Claire Gallois, Matteo Landi, et al.
Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study.
2025 · Martina Carullo, Beatrice Borelli, et al. · Journal of Clinical Oncology
Supplemental Figure 6 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2024 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 3 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2024 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2024 · Claire Gallois, Matteo Landi, et al.
Supplemental Figure 1 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2024 · Claire Gallois, Matteo Landi, et al.
Works count: 62
Citation count: 128
H-index: 4
I10-index: 2
Year
Topic
Type